Zynerba Pharmaceuticals Announces Presentations at the American Society for Experimental Neurotherapeutics (ASENT) 2020 Annual Meeting

ASENT

DEVON, PA — Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, announced the acceptance and presentation details of data being presented at the American Society for Experimental Neurotherapeutics (ASENT) 2020 Meeting. The meeting is being held in Bethesda, MD on March 2nd through March 5th, 2020.

“These new data are important, and help further elucidate the significance of the conditions we are treating in our clinical trials and the potential for positive impact of Zygel, if approved by the FDA,” said Joseph M. Palumbo, MD, FAPA, MACPsych, Chief Medical Officer of Zynerba. “We are committed to developing therapeutic interventions for children and adolescents with a variety of debilitating neuropsychiatric conditions including Fragile X syndrome and autism spectrum disorder.”

READ:  Annovis Bio Files Patent Application for Method of Inhibiting, Preventing, or Treating Neurological Injuries Due to Viral and Other Infections Including COVID-19

Accepted as poster and for presentation during The ASENT Pipeline Datablitz Short Presentation session

Poster Title: “Phase 2 BRIGHT (An open-label tolerability and efficacy study of ZYN002 administered as a transdermal gel to children and adolescents with autism spectrum disorder): Baseline characteristics”
Poster number: 27
Poster reception: Tuesday, March 3 from 5:00 to 6:00 PM and Wednesday, March 4 from 5:00 to 7:00 PM.
Presentation time: Wednesday, March 4 from 1:00 to 3:00 PM.

Poster Title: “Post-hoc Analysis – An open-label study of transdermal cannabidiol (ZYN002) for the treatment of Fragile X syndrome in children and adolescents: Estimating health state utility scores”
Poster number: 29
Poster reception: Tuesday, March 3 from 5:00 to 6:00 PM and Wednesday, March 4 from 5:00 to 7:00 PM.
Presentation time: Wednesday, March 4 from 1:00 to 3:00 PM.

Accepted as poster

READ:  Aclaris Therapeutics to Present at the Jefferies Virtual Healthcare Conference

Poster Title: “Fragile X syndrome diagnosis and patient journey: The caregivers’ perspective”
Poster number: 28
Poster reception: Tuesday, March 3 from 5:00 to 6:00 PM and Wednesday, March 4 from 5:00 to 7:00 PM.

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.

Buy Us a Cup of Coffee